The earnings call highlighted significant growth in key areas such as the Rx business and TeleClinic, supported by a successful capital increase and strategic innovations like the DocMorris Health Companion. However, challenges such as a decline in adjusted EBITDA and the impact of the Zur Rose pharmacy closure were also noted. The overall impression is of a company on a positive trajectory, despite some financial setbacks.

Company Guidance

During the call, the company provided guidance indicating strong performance and strategic initiatives for the fiscal year 2025. Notably, they achieved a 43.5% increase in Rx business revenues and a more than 150% year-on-year growth in TeleClinic revenues. For the full year, the company confirmed a revenue growth expectation of more than 10% and an EBITDA guidance ranging from minus CHF 35 million to minus CHF 55 million. They also highlighted a successful CHF 200 million capital increase with a 99% take-up rate, reflecting strong shareholder confidence. Additionally, the company made strides in AI innovation with the rollout of the DocMorris Health Companion, positioning themselves as a one-stop health platform. The non-Rx business continued to grow steadily at 4.4%, despite challenges like the closure of the Zur Rose pharmacy. Retail media and telemedicine were emphasized as key growth drivers, with TeleClinic expected to contribute around 10% of the total gross profit for 2025. Overall, the company outlined a strategic transformation towards becoming a seamless digital health platform, aiming to redefine healthcare for millions.

Rx Business Revenue Growth

The Rx business delivered strong growth with revenues increasing by 43.5% in the first half of 2025.

TeleClinic Revenue Surge

TeleClinic revenues grew by more than 150% year-on-year, contributing significantly to the company's gross profit.

Capital Increase Success

A CHF 200 million capital increase was successfully completed with a 99% take-up rate, reflecting strong shareholder support.

Launch of DocMorris Health Companion

The rollout of the DocMorris Health Companion leveraging AI innovation marks a strategic step forward in becoming a digital health platform.

Non-Rx Business Growth

The non-Rx business showed steady and profitable growth with revenues up 4.4% year-on-year.

Retail Media Business Expansion

The retail media business is scaling rapidly, with expected mid-single-digit million EBITDA contribution this year.

Gross Margin Improvement

Gross margin improved by 70 basis points year-on-year, driven by better pricing and increased contribution of high-margin service businesses.

DocMorris (CH:DOCM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CH:DOCM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 19, 2026	2025 (Q4)	- / -	-2.472	―	―	―
Aug 19, 2025	2025 (Q2)	-1.33 / -0.71	-1.586	55.04% (+0.87)	―	―
Mar 13, 2025	2024 (Q4)	-2.27 / -2.47	-2.511	1.55% (+0.04)	―	―
Aug 20, 2024	2024 (Q2)	-2.55 / -1.59	-2.465	35.66% (+0.88)	―	―
Mar 21, 2024	2023 (Q4)	-2.16 / -2.51	-3.738	32.83% (+1.23)	―	―
Aug 17, 2023	2023 (Q2)	-0.52 / -2.46	-4.082	39.61% (+1.62)	―	―
Mar 23, 2023	2022 (Q4)	-3.47 / -3.74	-7.57	50.62% (+3.83)	―	―
Aug 18, 2022	2022 (Q2)	-4.95 / -4.08	-3.954	-3.24% (-0.13)	―	―
Mar 24, 2022	2021 (Q4)	-3.81 / -7.57	-4.286	-76.62% (-3.28)	―	―
Aug 18, 2021	2021 (Q2)	-2.98 / -3.95	-2.89	-36.82% (-1.06)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CH:DOCM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 19, 2025	CHF7.66	CHF6.78	-11.49%
Mar 13, 2025	CHF10.40	CHF7.42	-28.65%
Aug 20, 2024	CHF23.53	CHF20.60	-12.45%
Mar 21, 2024	CHF39.29	CHF39.20	-0.23%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does DocMorris AG (CH:DOCM) report earnings?

DocMorris AG (CH:DOCM) is schdueled to report earning on Mar 19, 2026, TBA (Confirmed).

What is DocMorris AG (CH:DOCM) earnings time?

DocMorris AG (CH:DOCM) earnings time is at Mar 19, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of DocMorris AG stock?

The P/E ratio of DocMorris is N/A.

What is CH:DOCM EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing